ROYCE & ASSOCIATES LP reported AKERO THERAPEUTICS INC (AKRO) in 1 quarterly 13F filing from 2025 Q3 through 2025 Q3. Peak portfolio weight reached 0.02% in 2025 Q3. The latest visible filing shows AKRO at 0.02% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was ROYCE & ASSOCIATES LP's position in AKERO THERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
AKRO was reported at 0.02% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
These are the practical questions this page is built to answer before you even open the full history table.
ROYCE & ASSOCIATES LP reported AKRO across 1 quarterly 13F filings, from 2025 Q3 through 2025 Q3.
The largest reported portfolio weight for AKRO was 0.02% in 2025 Q3.
The most recent filing on this page is 2025 Q3, when ROYCE & ASSOCIATES LP reported 32,510 shares, equal to 0.02% of portfolio, with an estimated market value of $1.5M.
The chart compares ROYCE & ASSOCIATES LP's quarterly AKRO portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.